MEG
BMRN icon

Millstone Evans Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Millstone Evans Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26K Sell
22
-40
-65% -$2.19K ﹤0.01% 805
2026
Q1 		$3.5K Buy
+62
New +$3.62K ﹤0.01% 699

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millstone Evans Group's BMRN Position: Q2 2026 in Review

Millstone Evans Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 65% in Q2 2026, selling an estimated $2.19K and leaving 22 shares worth $1.26K. The position accounts for ﹤0.01% of the portfolio, ranked #805.

Millstone Evans Group first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.5K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Millstone Evans Group held 22 shares of BioMarin Pharmaceuticals worth $1.26K as of Q2 2026.
  • Millstone Evans Group sold 40 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.19K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Millstone Evans Group's portfolio in Q2 2026, its #805 holding.
  • Millstone Evans Group first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Millstone Evans Group's BioMarin Pharmaceuticals position peaked at $3.5K in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.